Physician Resources: Beta-Catenin & Hepatocellular Cancer: From bench to Bedside
In this CME, Satdarshan (Paul) S. Monga, MD discusses how to explain the molecular subclasses of hepatocellular cancers (HCCs) in particular the subclass driven by CTNNB1 mutations leading to Wnt-beta-catenin activation (around 35-40% of all HCCs), describe metabolic addiction of CTNNB1-mutated HCC that is a therapeutic vulnerability and being investigated in a clinical trial, and implement the management of CTNNB1-mutated HCC by direct targeting of beta-catenin using siRNA and lipid nanoparticle impacting tumor cell survival and immune microenvironment as a precision medicine clinical trial.
Target Audience
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the molecular subclasses of hepatocellular cancers (HCCs) in particular the subclass driven by CTNNB1 mutations leading to Wnt-beta-catenin activation (around 35-40% of all HCCs)
- Describe metabolic addiction of CTNNB1-mutated HCC that is a therapeutic vulnerability and being investigated in a clinical trial
- Implement the management of CTNNB1-mutated HCC by direct targeting of beta-catenin using siRNA and lipid nanoparticle impacting tumor cell survival and immune microenvironment as a precision medicine clinical trial
Course summary
- 1.00 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 1.00 Attendance
Satdarshan (Paul) Singh Monga, MD
SVC Chair in Pathobiology and Therapeutics Chair and Professor of Pharmacology Professor of Medicine Director, Organ Pathobiology and Therapeutics Institute Director, Pittsburgh Liver Research Center Associate Dean of Research, School
Available Credit
- 1.00 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 1.00 Attendance

Facebook
X
LinkedIn
Forward